

# Lennie P G Derde

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4108629/publications.pdf>

Version: 2024-02-01

51  
papers

10,962  
citations

147726

31  
h-index

182361

51  
g-index

56  
all docs

56  
docs citations

56  
times ranked

17480  
citing authors

#	ARTICLE	IF	CITATIONS
1	Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19). <i>Intensive Care Medicine</i> , 2020, 46, 854-887.	3.9	1,536
2	Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19. <i>New England Journal of Medicine</i> , 2021, 384, 1491-1502.	13.9	1,419
3	A minimal common outcome measure set for COVID-19 clinical research. <i>Lancet Infectious Diseases</i> , The, 2020, 20, e192-e197.	4.6	1,165
4	Surviving Sepsis Campaign: Guidelines on the Management of Critically Ill Adults with Coronavirus Disease 2019 (COVID-19). <i>Critical Care Medicine</i> , 2020, 48, e440-e469.	0.4	816
5	Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19. <i>New England Journal of Medicine</i> , 2021, 385, 790-802.	13.9	778
6	Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19. <i>New England Journal of Medicine</i> , 2021, 385, 777-789.	13.9	712
7	Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 1317.	3.8	671
8	Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 499.	3.8	498
9	Interventions to reduce colonisation and transmission of antimicrobial-resistant bacteria in intensive care units: an interrupted time series study and cluster randomised trial. <i>Lancet Infectious Diseases</i> , The, 2014, 14, 31-39.	4.6	297
10	Surviving Sepsis Campaign Guidelines on the Management of Adults With Coronavirus Disease 2019 (COVID-19) in the ICU: First Update. <i>Critical Care Medicine</i> , 2021, 49, e219-e234.	0.4	289
11	The REMAP-CAP (Randomized Embedded Multifactorial Adaptive Platform for Community-acquired) Tj ETQq1 1 0.784314 rgBT /Overlo 1.5 245	1.5	245
12	Personal protective equipment and intensive care unit healthcare worker safety in the COVID-19 era (PPE-SAFE): An international survey. <i>Journal of Critical Care</i> , 2020, 59, 70-75.	1.0	234
13	Adaptive platform trials: definition, design, conduct and reporting considerations. <i>Nature Reviews Drug Discovery</i> , 2019, 18, 797-807.	21.5	218
14	A guide to immunotherapy for COVID-19. <i>Nature Medicine</i> , 2022, 28, 39-50.	15.2	206
15	Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials. <i>Nature Communications</i> , 2021, 12, 2349.	5.8	194
16	Influenza-associated Aspergillosis in Critically Ill Patients. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 196, 524-527.	2.5	176
17	Effect of Convalescent Plasma on Organ Support and Free Days in Critically Ill Patients With COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 1690.	3.8	169
18	MLST reveals potentially high-risk international clones of <i>Enterobacter cloacae</i> *. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 48-56.	1.3	131

#	ARTICLE	IF	CITATIONS
19	Clinical impact and risk factors for colonization with extended-spectrum $\beta$ -lactamase-producing bacteria in the intensive care unit. <i>Intensive Care Medicine</i> , 2012, 38, 1769-1778.	3.9	120
20	Chlorhexidine body washing to control antimicrobial-resistant bacteria in intensive care units: a systematic review. <i>Intensive Care Medicine</i> , 2012, 38, 931-939.	3.9	106
21	Anticoagulant interventions in hospitalized patients with COVID-19: A scoping review of randomized controlled trials and call for international collaboration. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2958-2967.	1.9	98
22	Effect of Antiplatelet Therapy on Survival and Organ Support-Free Days in Critically Ill Patients With COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 2022, 327, 1247.	3.8	83
23	The Association Between Colonization With Carbapenemase-Producing Enterobacteriaceae and Overall ICU Mortality. <i>Critical Care Medicine</i> , 2015, 43, 1170-1177.	0.4	77
24	Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial. <i>Intensive Care Medicine</i> , 2021, 47, 867-886.	3.9	65
25	The Transmissibility of Antibiotic-Resistant Enterobacteriaceae in Intensive Care Units. <i>Clinical Infectious Diseases</i> , 2018, 66, 489-493.	2.9	61
26	Dysregulated Innate and Adaptive Immune Responses Discriminate Disease Severity in COVID-19. <i>Journal of Infectious Diseases</i> , 2021, 223, 1322-1333.	1.9	61
27	Duration of colonization with antimicrobial-resistant bacteria after ICU discharge. <i>Intensive Care Medicine</i> , 2014, 40, 564-571.	3.9	55
28	Randomised clinical trials in critical care: past, present and future. <i>Intensive Care Medicine</i> , 2022, 48, 164-178.	3.9	46
29	Molecular epidemiology of MRSA in 13 ICUs from eight European countries. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 45-52.	1.3	43
30	Survey of metallo- $\beta$ -lactamase-producing Enterobacteriaceae colonizing patients in European ICUs and rehabilitation units, 2008-11. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 1981-1988.	1.3	41
31	Global outbreak research: harmony not hegemony. <i>Lancet Infectious Diseases</i> , The, 2020, 20, 770-772.	4.6	40
32	KPC-Like Carbapenemase-Producing Enterobacteriaceae Colonizing Patients in Europe and Israel. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 1912-1917.	1.4	37
33	Characterization of pKP-M1144, a Novel ColE1-Like Plasmid Encoding IMP-8, GES-5, and BEL-1 $\beta$ -Lactamases, from a <i>Klebsiella pneumoniae</i> Sequence Type 252 Isolate. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 5065-5068.	1.4	30
34	Characterisation of IncA/C2 plasmids carrying an In416-like integron with the blaVIM-19 gene from <i>Klebsiella pneumoniae</i> ST383 of Greek origin. <i>International Journal of Antimicrobial Agents</i> , 2016, 47, 158-162.	1.1	25
35	Phylogenetic lineages, clones and $\beta$ -lactamases in an international collection of <i>Klebsiella oxytoca</i> isolates non-susceptible to expanded-spectrum cephalosporins. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, dkv273.	1.3	24
36	Antimicrobial stewardship in ICUs during the COVID-19 pandemic: back to the 90s?. <i>Intensive Care Medicine</i> , 2021, 47, 104-106.	3.9	22

#	ARTICLE	IF	CITATIONS
37	The European clinical research response to optimise treatment of patients with COVID-19: lessons learned, future perspective, and recommendations. <i>Lancet Infectious Diseases</i> , The, 2022, 22, e153-e158.	4.6	22
38	Sudden cardiac arrest as a presentation of Brugada syndrome unmasked by thyroid storm. <i>BMJ Case Reports</i> , 2015, 2015, bcr2015212351.	0.2	16
39	Association between tocilizumab, sarilumab and all-cause mortality at 28 days in hospitalised patients with COVID-19: A network meta-analysis. <i>PLoS ONE</i> , 2022, 17, e0270668.	1.1	16
40	Oropharyngeal decontamination in intensive care patients: less is not more. <i>Critical Care</i> , 2009, 13, 183.	2.5	15
41	Statement paper on diversity for the European Society of Intensive Care Medicine (ESICM). <i>Intensive Care Medicine</i> , 2019, 45, 1002-1005.	3.9	14
42	Culture-based detection of methicillin-resistant <i>Staphylococcus aureus</i> by a network of European laboratories: an external quality assessment study. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2012, 31, 1765-1770.	1.3	11
43	The Diagnostic Yield of Routine Admission Blood Cultures in Critically Ill Patients. <i>Critical Care Medicine</i> , 2021, 49, 60-69.	0.4	9
44	Moderate positive predictive value of a multiplex real-time PCR on whole blood for pathogen detection in critically ill patients with sepsis. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2019, 38, 1829-1836.	1.3	6
45	Thrombosis pathways in COVID-19 versus influenza-associated ARDS: a targeted proteomics approach. <i>Journal of Thrombosis and Haemostasis</i> , 2022, , .	1.9	4
46	Focus on clinical trial interpretation. <i>Intensive Care Medicine</i> , 2020, 46, 790-792.	3.9	2
47	Control of colonisation with extended-spectrum $\beta$ -lactamase-producing bacteria: reply to Zandstra et al.. <i>Intensive Care Medicine</i> , 2013, 39, 540-540.	3.9	1
48	Contact Precautions for Patients With Multidrug-Resistant Pathogens. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 629.	3.8	1
49	How COVID-19 will change the management of other respiratory viral infections. <i>Intensive Care Medicine</i> , 2021, 47, 1148-1151.	3.9	1
50	Care bundles in intensive care units – Authors' reply. <i>Lancet Infectious Diseases</i> , The, 2014, 14, 372.	4.6	0
51	The authors reply. <i>Critical Care Medicine</i> , 2015, 43, e537-e538.	0.4	0